Samsung Biologics to Invest US$280 Million to Expand Biologics Manufacturing in Maryland
Introduction:
Samsung Biologics has announced plans to invest US$280 million to acquire a biologics manufacturing facility in Rockville, Maryland, USA.
Features:
The Rockville site includes two cGMP manufacturing plants with a combined capacity of 60,000 litres, supporting both clinical and commercial production at small and large scales.
Additional investment is planned to expand capacity and upgrade technology at the facility.
Existing manufacturing activities at the site will continue after the acquisition.
The facility will be integrated into a global network, enabling multi-site production across the U.S. and Korea.
The combined manufacturing capacity across all operational plants totals 785,000 litres, supporting products including monoclonal antibodies, antibody-drug conjugates, mRNA therapies, organoid-based platforms, and next-generation biologics.
The acquisition strengthens U.S.-based biologics manufacturing operations.
Completion of the acquisition is expected by the end of the first quarter of 2026, after which the facility will be part of global operations.
Specifications:
| Name | Samsung Biologics |
| Type | New Construction |
| Budget | US$280 million |
| Year | 2026 |
